ProfileGDS4814 / ILMN_1904111
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 65% 69% 70% 71% 67% 66% 70% 70% 70% 73% 69% 67% 70% 71% 69% 66% 71% 69% 70% 72% 67% 68% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)60.376965
GSM780708Untreated after 4 days (C2_1)70.999269
GSM780709Untreated after 4 days (C3_1)73.465370
GSM780719Untreated after 4 days (C1_2)75.408971
GSM780720Untreated after 4 days (C2_2)64.985767
GSM780721Untreated after 4 days (C3_2)63.571566
GSM780710Trastuzumab treated after 4 days (T1_1)74.215270
GSM780711Trastuzumab treated after 4 days (T2_1)74.441470
GSM780712Trastuzumab treated after 4 days (T3_1)74.550270
GSM780722Trastuzumab treated after 4 days (T1_2)85.817873
GSM780723Trastuzumab treated after 4 days (T2_2)68.942369
GSM780724Trastuzumab treated after 4 days (T3_2)63.631467
GSM780713Pertuzumab treated after 4 days (P1_1)73.273270
GSM780714Pertuzumab treated after 4 days (P2_1)75.351371
GSM780715Pertuzumab treated after 4 days (P3_1)68.798769
GSM780725Pertuzumab treated after 4 days (P1_2)63.377966
GSM780726Pertuzumab treated after 4 days (P2_2)77.799871
GSM780727Pertuzumab treated after 4 days (P3_2)71.317569
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)74.393970
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)81.891272
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)64.584467
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)68.068768
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)63.674467